Opportunity ID: 346816
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | HT9425-23-TSCRP-EHDA |
Funding Opportunity Title: | DoD Tuberous Sclerosis Complex, Exploration – Hypothesis Development Award |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Cooperative Agreement Grant |
Category of Funding Activity: | Science and Technology and other Research and Development |
Category Explanation: | – |
Expected Number of Awards: | 5 |
Assistance Listings: | 12.420 — Military Medical Research and Development |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 2 |
Posted Date: | Mar 14, 2023 |
Last Updated Date: | Jun 26, 2023 |
Original Closing Date for Applications: | Jul 07, 2023 |
Current Closing Date for Applications: | Jul 07, 2023 |
Archive Date: | Aug 06, 2023 |
Estimated Total Program Funding: | $1,200,000 |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
Additional Information on Eligibility: | – |
Additional Information
Agency Name: | Dept. of the Army — USAMRAA |
Description: |
The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a strong scientific rationale and study design. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.
The following are important aspects of the EHDA:
· Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of the award mechanism.
Although not all-inclusive, the following examples are ways in which the proposed research project may be innovative:
○ Explores a novel idea and/or research question in TSC research and/or patient care.
○ Uses or develops novel methods or technologies to address a question in TSC research and/or patient care.
○ Applies or adapts existing methods or technologies for novel TSC research or clinical purposes that differ fundamentally from those originally intended. |
Link to Additional Information: | – |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
Version | Modification Description | Updated Date |
---|---|---|
A small correction was made to page 6 of the Program Announcement to correct the referenced attachment number for the Animal Research Plan. The correct attachment number is attachment 9 for the Animal Research Plan. | Jun 26, 2023 | |
Mar 14, 2023 |
DISPLAYING: Synopsis 2
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | HT9425-23-TSCRP-EHDA |
Funding Opportunity Title: | DoD Tuberous Sclerosis Complex, Exploration – Hypothesis Development Award |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Cooperative Agreement Grant |
Category of Funding Activity: | Science and Technology and other Research and Development |
Category Explanation: | – |
Expected Number of Awards: | 5 |
Assistance Listings: | 12.420 — Military Medical Research and Development |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 2 |
Posted Date: | Mar 14, 2023 |
Last Updated Date: | Jun 26, 2023 |
Original Closing Date for Applications: | Jul 07, 2023 |
Current Closing Date for Applications: | Jul 07, 2023 |
Archive Date: | Aug 06, 2023 |
Estimated Total Program Funding: | $1,200,000 |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
Additional Information on Eligibility: | – |
Additional Information
Agency Name: | Dept. of the Army — USAMRAA |
Description: |
The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a strong scientific rationale and study design. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.
The following are important aspects of the EHDA:
· Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of the award mechanism.
Although not all-inclusive, the following examples are ways in which the proposed research project may be innovative:
○ Explores a novel idea and/or research question in TSC research and/or patient care.
○ Uses or develops novel methods or technologies to address a question in TSC research and/or patient care.
○ Applies or adapts existing methods or technologies for novel TSC research or clinical purposes that differ fundamentally from those originally intended. |
Link to Additional Information: | – |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
DISPLAYING: Synopsis 1
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | HT9425-23-TSCRP-EHDA |
Funding Opportunity Title: | DoD Tuberous Sclerosis Complex, Exploration – Hypothesis Development Award |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Cooperative Agreement Grant |
Category of Funding Activity: | Science and Technology and other Research and Development |
Category Explanation: | – |
Expected Number of Awards: | 5 |
Assistance Listings: | 12.420 — Military Medical Research and Development |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Mar 14, 2023 |
Last Updated Date: | Mar 14, 2023 |
Original Closing Date for Applications: | – |
Current Closing Date for Applications: | Jul 07, 2023 |
Archive Date: | Aug 06, 2023 |
Estimated Total Program Funding: | $1,200,000 |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
Additional Information on Eligibility: | – |
Additional Information
Agency Name: | Dept. of the Army — USAMRAA |
Description: |
The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a strong scientific rationale and study design. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.
The following are important aspects of the EHDA:
· Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of the award mechanism.
Although not all-inclusive, the following examples are ways in which the proposed research project may be innovative:
○ Explores a novel idea and/or research question in TSC research and/or patient care.
○ Uses or develops novel methods or technologies to address a question in TSC research and/or patient care.
○ Applies or adapts existing methods or technologies for novel TSC research or clinical purposes that differ fundamentally from those originally intended. |
Link to Additional Information: | – |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Related Documents
Packages
Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
PKG00280513 | Mar 14, 2023 | Jul 07, 2023 | View |